The global Pediatric Clinical Trial Market is set to experience steady growth over the next decade, with market value projected to increase from USD 17.9 billion in 2024 to an estimated USD 31.7 billion by 2034, expanding at a compound annual growth rate (CAGR) of 5.9% during the forecast period.
This follows strong historical growth, with the market valued at USD 16.8 billion in 2023, driven by a CAGR of 6.5% between 2019 and 2023.
The anticipated growth in the pediatric clinical trial market is driven by rising investments in research and development, increasing awareness of the need for specialized pediatric treatments, and advancements in clinical trial methodologies.
In 2021, the oncology therapeutic field category had the world’s second-largest revenue share. Cancer is the top cause of death in the globe. Cancer cases in children under the age of 19 are anticipated to reach 291,000 by 2040. With the increasing number of pediatric cancer cases worldwide, many hospitals and institutes are focusing on the development of therapeutic drugs, resulting in an increase in the number of pediatric clinical trials globally.
Irrespective of all these growth factors, the global market for pediatric clinical trials can be hindered for some specific reasons. The high rate of pediatric clinical trial discontinuation for a number of reasons is expected to impede growth in the pediatric clinical trials market. Pediatric studies have a high failure rate due to reasons such as patient enrollment. Other concerns include behavioral disorders and trial conduct issues such as inappropriate dosing, formulation difficulty, and informative termination, as well as regulatory challenges and pharmaceutical toxicity during clinical investigations.
Leading Companies Profiled in Pediatric Clinical Trials Market are
- Synteract
- ICON Plc.
- Syneos Health
- Medpace, Inc
- PPD Inc.
- Premier Research
- LabCorp Drug Development
- QPS Holding
- Pfizer Inc.
- The Emmes Company, LLC
- IQVIA Inc.
Key Takeaways :
- In 2022, the global pediatric clinical trials market is estimated to have a global market size of US$ 15.8 Billion
- The pediatric clinical trials market in North America to acquire 45% of the global market share
- APAC projected to acquire 25% of the global market share
- By phase, the phase II clinical trials segment took over 33% of the global pediatric clinical trials market share
- By study design, the treatment studies for clinical trials acquired 66% of the global market share
- By therapeutic area, the oncology therapeutic area segment acquired almost 17% of the global market share
“The rising prevalence of chronic and hereditary diseases in children is driving this market to conduct more studies to improve treatment efficiency. Simultaneously, many clinical trials for COVID-19 vaccinations for children are being done, which is predicted to greatly increase market development. ” comments a Future Market Insights analyst.
A Old Full Report Analysis Click Here
Key Segments:
Pediatric Clinical Trials Market by Phase Type:
- Phase I Pediatric Clinical Trials
- Phase II Pediatric Clinical Trials
- Phase III Pediatric Clinical Trials
- Phase IV Pediatric Clinical Trials
Pediatric Clinical Trials Market by Study Design:
- Treatment Studies of Pediatric Clinical Trials
- Observational Studies of Pediatric Clinical Trials
Pediatric Clinical Trials Market by Therapeutic Areas:
- Pediatric Clinical Trials for Infectious Diseases
- Pediatric Clinical Trials for Oncology
- Pediatric Clinical Trials for Autoimmune/Inflammatory Diseases
- Pediatric Clinical Trials for Respiratory Disorders
- Pediatric Clinical Trials for Mental Health Disorders
- Pediatric Clinical Trials for Other Therapeutic Areas
Pediatric Clinical Trials Market by Region:
- North American Pediatric Clinical Trials Market
- Europe Pediatric Clinical Trials Market
- Asia Pacific Pediatric Clinical Trials Market
- Middle East & African Pediatric Clinical Trials Market
- Latin America Pediatric Clinical Trials Market
Competitive Landscape
The industry analyzed is consolidated due to the sheer existence of a few key competitors in the market, with very few extra participants. Market participants’ key strategies included trial initialization, acquisitions, and collaborations.
- In March 2022, Pfizer initiated a Phase 2/3 study for PAXLOVID tablets, which are specifically designed to treat COVID-19 in young patients. PAXLOVID reduced the risk of hospitalization or death from any cause by 89 percent (within three days of symptom onset) and 88 percent (within five days of appearance of symptoms).
- In April 2021, Novartis announced plans to initiate SMART, a Phase 3b clinical trial to examine the safety and efficacy of Zolgensma (onasemnogene abeparvovec) in young children with spinal muscular atrophy.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
